About this episode
The FDA's rejection of MDMA as a treatment may well be a short-term setback for legally helping people with PTSD and other disorders. Mason Marks of Harvard Law School’s Petrie-Flom Center for Health Law Policy offers his assessment.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Cato Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
